SCHEDULE: Armistice Capital Discloses 9.99% Stake in Imunon, Inc.

Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, reporting beneficial ownership of 450,315 shares, representing 9.99% of Imunon, Inc.'s common stock.

Summary

• Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, indicating their beneficial ownership of 450,315 shares of Imunon, Inc. common stock.
• This holding represents 9.99% of the total class of securities.
• The filing is an amendment (Amendment No. 2) and the event date requiring the filing is June 30, 2026.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd is the managing member of Armistice Capital, LLC.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, primarily due to the passive nature of the ownership disclosure and the lack of new strategic information. The significant stake held by Armistice Capital, while noted, does not inherently signal positive or negative momentum without further context on their intentions.

Positives

• Armistice Capital, LLC, an investment manager, has taken a significant stake (9.99%) in Imunon, Inc., which could signal confidence in the company's long-term prospects.
• The filing clearly delineates the ownership structure, with Armistice Capital Master Fund Ltd. as the direct holder and Armistice Capital, LLC exercising investment and voting power.

Negatives

• The filing is a Schedule 13G, which typically indicates passive investment, suggesting no immediate intention to influence or control the company's management or policies.
• The filing is an amendment, implying previous disclosures, but does not provide new strategic information or operational updates from Imunon, Inc. itself.

Risks

• The primary risk is that the passive nature of the investment by Armistice Capital could mean a lack of active engagement in improving company performance or strategy.
• While holding 9.99%, there is no indication of future intentions, which could lead to uncertainty for other shareholders if Armistice Capital decides to divest its stake.

Future Outlook

This filing does not contain forward-looking statements or guidance from Imunon, Inc. It is a disclosure of beneficial ownership by an investment entity.

Management Comments

• Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that significant stakes disclosed via Schedule 13G filings often indicate a substantial institutional investor's interest. However, the passive nature of this filing suggests Armistice Capital is currently a portfolio holder rather than an activist investor, which is common in the biotechnology and pharmaceutical sectors where Imunon, Inc. likely operates, given its name.

Comparison to Industry Standards

• The 9.99% ownership threshold is a common level for institutional investors to reach before requiring more detailed disclosures or potentially engaging more actively with a company.
• Many investment funds, such as those managed by BlackRock, Vanguard, or State Street, hold similar or larger passive stakes in publicly traded companies across various sectors, including healthcare and biotechnology.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an investment manager may influence market perception, but the passive nature suggests no immediate change in corporate control or strategy.
• Creditors: No direct impact is indicated as the filing pertains to equity ownership and not debt.
• Employees: No direct impact is indicated as the filing does not concern operational changes or restructuring.

Next Steps

• Monitor future filings from Armistice Capital for any changes in beneficial ownership.
• Observe Imunon, Inc.'s operational and financial performance to assess the impact of significant institutional holdings.

Key Dates

Keywords

Imunon, Armistice Capital, Schedule 13G, Beneficial Ownership, Investment Management, Common Stock, Securities